SOURCE: Equity News Circuit

Equity News Circuit

January 29, 2013 08:15 ET

Free Research Reports on AKS, HMSY, KERX and RPRX Issued by the Bedford Report

Note to Editors: The Following Is an Investment Opinion Being Issued by the EQUITY NEWS CIRCUIT

NEW YORK, NY--(Marketwire - Jan 29, 2013) - The Bedford Report has released new equity reports today. As a leading provider of free in depth reports and timely market updates, Bedford is an essential resource for hundreds of thousands of investors across the country.

AK Steel Holding Corporation (NYSE: AKS) shares fell 8 percent on over 10 million shares traded Monday. Analysts at Goldman Sachs have recently downgraded steel sector to cautious and lowered AK Steel's rating to "sell" from "neutral".

Find out more about AK Steel including full access to the free equity report at: www.BedfordReport.com/AKS

HMS Holdings Corp. (NASDAQ: HMSY) provides cost containment services to Government and private healthcare payers and sponsors. Shares of the company fell sharply on over 1 million shares traded Monday after Oppenheimer downgraded the company's rating to "perform" from "outperform".

Find out more about HMS Holdings including full access to the free equity report at: www.BedfordReport.com/HMSY

Keryx Biopharmaceuticals (NASDAQ: KERX) shares soared 90 percent on nearly 50 million shares traded Monday. The company reported Zerenex met primary and all key secondary endpoints in a long-term Phase 3 study as a treatment for hyperphosphatemia in patients with end-stage renal disease on dialysis.

Find out more about Keryx Biopharmaceuticals including full access to the free equity report at: www.BedfordReport.com/KERX

Repros Therapeutics Inc. (NASDAQ: RPRX) shares plunged 30 percent on over 4.6 million shares traded Monday, which was more than 15 times its average daily volume. The company now expects to release clinical results from the first pivotal study of Androxal in the treatment of secondary hypogonadism in Q3 2013 instead of Q2 2013.

Find out more about Repros Therapeutics including full access to the free equity report at: www.BedfordReport.com/RPRX

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein.

A third party, Providence Media Strategies LLC has paid Equity News Circuit five hundred dollars for the publication of this news release. Neither Equity News Circuit, nor the hiring party, has a financial relationship with any company whose stock is mentioned in this release. Neither Equity News Circuit nor the hiring party are a registered investment advisor, and nothing in this report is intended as a solicitation to buy or sell any security.

Contact Information